ÂÜÀòÂÒÂ×

M. Craig Shepherd is a Senior Managing Director in the Blackstone Life Sciences group and a member of its Investment Committee. Since joining Blackstone in New York in 2017, Mr. Shepherd has played a leadership role in Blackstone’s acquisition of Clarus in 2018 and Blackstone’s $2 billion investment with Alnylam Pharmaceuticals in 2020.

Prior to Blackstone, Mr. Shepherd was a Managing Director and a member of the Investment Committee at DRI Capital, a life sciences private equity firm dedicated to the acquisition of pharmaceutical royalties through its managed funds Drug Royalty I, II and III. He joined DRI from Amgen where he held roles in Amgen’s global HQ in California and its international HQ in Switzerland.

Mr. Shepherd holds an MBA from Harvard Business School, a law degree from McGill University, and a BA from the University of Western Ontario. Mr. Shepherd is a member of the Healthcare Advisory Board of the Partnership Fund for New York City and a member of the McGill University Chancellor’s Advisory Board.